Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models
Yuji Piao(The University of Texas MD Anderson Cancer Center), John de Groot(University of California, San Francisco)
Cited by 67
Related Papers
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages
|Neuro-Oncology|2019|165
Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma
|Oncotarget|2012|84
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent <i>IDH</i> wild-type glioblastoma
|Neuro-Oncology Advances|2022|61
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1
|Acta Neuropathologica|2022|50